Back to Search
Start Over
Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry.
- Source :
-
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2019 Sep 01; Vol. 94 (3), pp. 342-347. Date of Electronic Publication: 2018 Dec 18. - Publication Year :
- 2019
-
Abstract
- Background: The bio-engineered COMBO stent (OrbusNeich Medical BV, The Netherlands) is a dual-therapy pro-healing stent. This novel technology may allow a shorter duration of dual antiplatelet therapy (DAPT) after stenting. We present the first 3 year clinical outcomes of patients treated with COMBO stent.<br />Methods and Results: The prospective, multicenter, investigator-initiated, all-comers REMEDEE Registry evaluates clinical outcomes after COMBO stent treatment. A 1,000 patients were enrolled between June 2013 and March 2014. Patients had a mean of 65 years ±11, 26% of the patients were females and 18% diabetics. More than 50% of patients presented with acute coronary syndrome, 60% of treated lesions were AHA/ACC lesion type B2 or C. Target lesion failure (TLF) at 3 year follow-up occurred in 10.7% of patients (N = 105). The separate components cardiac death, target vessel myocardial infarction and target lesion revascularization occurred in 4.1%, 2.0%, and 7.1%, respectively of patients. Definite stent thrombosis (ST) was observed in 0.7% of all patients. At 3-year follow-up there were only 73 patients taking DAPT.<br />Conclusions: At 3-year follow-up, patients treated with COMBO stent in the present large prospective all-comers cohort, continue to show good clinical outcomes. Clinicaltrials.gov identifier: NCT01874002.<br />Condensed Abstract: The COMBO stent is a sirolimus-eluting stent with a luminal anti-CD34-antibody layer, that binds endothelial progenitor cells. These cells can differentiate to endothelial cells and stimulate early endothelialization of the stent. The REMEDEE Registry is the first large, multicenter, prospective, cohort study evaluating the clinical outcomes of 1,000 all-comers patients treated with COMBO stent. Target lesion failure at 3 year follow-up was 10.7% and the rate of definite ST was 0.7%.<br /> (© 2018 Wiley Periodicals, Inc.)
- Subjects :
- Acute Coronary Syndrome diagnostic imaging
Acute Coronary Syndrome mortality
Aged
Coronary Artery Disease diagnostic imaging
Coronary Artery Disease mortality
Coronary Thrombosis etiology
Europe
Female
Humans
Male
Middle Aged
Percutaneous Coronary Intervention adverse effects
Percutaneous Coronary Intervention mortality
Prospective Studies
Registries
Risk Factors
Time Factors
Treatment Outcome
Acute Coronary Syndrome therapy
Coronary Artery Disease therapy
Percutaneous Coronary Intervention instrumentation
Stents
Subjects
Details
- Language :
- English
- ISSN :
- 1522-726X
- Volume :
- 94
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
- Publication Type :
- Academic Journal
- Accession number :
- 30565371
- Full Text :
- https://doi.org/10.1002/ccd.28047